---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-220691"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2026-05-13T12:32:07+00:00"
generated_at: "2026-05-13T12:35:32.178335+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics Q1 2026: $174.8M cash, $1.3M revenue; FT819 lupus trial on track

## Summary
- Cash, equivalents, and investments of $174.8M as of March 31, 2026; operating runway extended into 2028.
- Total revenue $1.3M from Ono Pharmaceutical collaboration; total operating expenses $34.3M (R&D $24.7M, G&A $9.6M, including $3.9M stock-based comp).
- RECLAIM-LN Phase 2 potentially registrational trial of FT819 for lupus nephritis on track to initiate in H2 2026; approximately 53 patients planned.
- FT819 selected into FDA CDRP program for enhanced CMC engagement; also has RMAT designation for SLE.
- FT839 IND planned H2 2026 for autoimmune diseases; FT836 Phase 1 enrolling solid tumor patients with no ICANS/GvHD/CRS or DLTs observed.

## SEC filing metadata
- accession: 0001193125-26-220691
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2026-05-13T12:32:07+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312526220691/0001193125-26-220691-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312526220691/fate-20260513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-220691
- JSON: https://secwatch.observer/filing/0001193125-26-220691.json
- Plain text: https://secwatch.observer/filing/0001193125-26-220691.txt

## Key facts
- Earnings Releases
  FATE THERAPEUTICS INC reported financial results for the first quarter ended March 31, 2026.
  - Period: the first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 13, 2026, Fate Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312526220691/0001193125-26-220691-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.